Anavex Presents Results From Phase IIb/III Trial Of Blarcamesine In Alzheimer's Disease
29/7 03:18
(RTTNews) - Anavex Life Sciences Corp. (AVXL) presented results from the Phase IIb/III study showing that blarcamesine (ANAVEX 2-73), once daily orally, significantly slowed clinical decline in people with early Alzheimer's disease or AD....